Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for AdaptHealth (AHCO) over the last 8 years, with Q3 2025 value amounting to -$56.6 million.

  • AdaptHealth's Cash from Financing Activities rose 538.14% to -$56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$323.2 million, marking a year-over-year decrease of 7117.29%. This contributed to the annual value of -$198.9 million for FY2024, which is 11501.49% down from last year.
  • Per AdaptHealth's latest filing, its Cash from Financing Activities stood at -$56.6 million for Q3 2025, which was up 538.14% from -$156.6 million recorded in Q2 2025.
  • AdaptHealth's 5-year Cash from Financing Activities high stood at $1.2 billion for Q1 2021, and its period low was -$156.6 million during Q2 2025.
  • In the last 5 years, AdaptHealth's Cash from Financing Activities had a median value of -$19.7 million in 2022 and averaged $51.2 million.
  • In the last 5 years, AdaptHealth's Cash from Financing Activities skyrocketed by 200794.02% in 2021 and then tumbled by 45809.85% in 2024.
  • Quarter analysis of 5 years shows AdaptHealth's Cash from Financing Activities stood at -$21.7 million in 2021, then rose by 28.19% to -$15.6 million in 2022, then crashed by 181.32% to -$43.9 million in 2023, then decreased by 23.06% to -$54.0 million in 2024, then fell by 4.86% to -$56.6 million in 2025.
  • Its last three reported values are -$56.6 million in Q3 2025, -$156.6 million for Q2 2025, and -$56.0 million during Q1 2025.